Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival in pancreatic cancer

Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival in pancreatic cancer

Results: Monotherapy with CCKR blockade significantly decreased tumor size and metastases in SCID mice with orthotopic PDAC. Tumor immuno-histochemical staining and flow cytometry demonstrated that the tumors of mice treated with the combination regimen had a significant reduction in Foxp3+ T-regula...

Full description

Saved in:
Bibliographic Details
Published in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 17; no. 4; pp. S3 - S4
Main Authors: Smith, Jill, Wang, Shangzi, Nadella, Sandeep, Jablonski, Sandra, Weiner, Louis
Format: Journal Article
Language:English
Published: Philadelphia Elsevier B.V 01-09-2017
Elsevier Limited
Subjects:
Cancer therapies
Cholecystokinin
Combination therapy
Fibroblasts
Flow cytometry
Immune checkpoint
Immunoglobulins
Lymphocytes
Medical prognosis
Metastasis
Pancreatic cancer
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Results: Monotherapy with CCKR blockade significantly decreased tumor size and metastases in SCID mice with orthotopic PDAC. Tumor immuno-histochemical staining and flow cytometry demonstrated that the tumors of mice treated with the combination regimen had a significant reduction in Foxp3+ T-regulatory cells and an increase in CD4+ and CD8+ lymphocytes.
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2017.07.016